This FDA funding opportunity supports research projects that utilize real-world data and algorithmic analyses to evaluate post-market clinical outcomes in patients switching among therapeutically equivalent complex generic drug products and reference listed drugs. The U01 mechanism prohibits clinical trials, focusing on observational and data-driven approaches to improve drug safety and effectiveness understanding.
Eligibility details are not specified in the grant listing. Contact the Food and Drug Administration for requirements.
